product launch vs takeover

Which will get there first?

My crystal ball sees a takeover before March - can't see Big Pharma waiting on the sidelines for OmaPro to test the market.

It's likely that OmaPro will build sales quickly and push CXS out of reach of those companies scouting about the biotech scene looking for bargains at the moment. It wouldn't surprise to see $2.50-$3 per share on launch.


Obviously my preference is still for CXS to go it alone in the USA, with a partnership deal for Europe. If we must raise another $20 million to do so, then so be it. It won't be at 43cps.